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Table. Outcomes after CEA
Variable
30-day 5-year
Overall (n¼ 231) Group 1 (n ¼ 58) Group 2 (n ¼ 173)
P
Overall Group 1 Group 2
PNo. (%) No. (%) No. (%) (%) (%) (%)
Stroke + death 6 (2.6) 4 (6.9) 2 (1.2) .29 24 37 20 .07
Death 1 (0.4) 0 (0) 1 (0.6) .81 20 29 18 .57
Stroke 5 (2.2) 4 (6.9) 1 (0.6) .07 7.0 11 5.5 .03
MI 4 (1.7) 0 (0) 4 (2.3) .24 1.8 0 2.4 .24
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Volume 59, Number 6S Abstracts 63Sartery stenosis (CAS) were reviewed. In group 1 symp-
toms (minor stroke, transient ischemic attack, TIA)
occurred #14 days; and in group 2 symptoms occurred
>14 days before CEA. Primary end points were com-
bined stroke and death; secondary end points were
stroke, death, and myocardial infarction (MI).
Results: A total of 231 CEAs were performed in 226
symptomatic patients (32% female; mean age, 72 6 8.7
years), comprising 58 (25%) in group 1 and 173 (75%) in
group 2. Sixty patients (26%) presented with stroke
(group1, 19%; group 2, 28%; P ¼ .16). The 30-day stroke
and death rate was 2.6% and not signiﬁcantly different be-
tween groups (Table). Three of four early strokes in group
1 occurred in patients with repeated transient ischemic at-
tacks #2 days before CEA. Mean follow-up was 3.9 years
(range, 30 days-10.8 years). The Table presents 5-year out-
comes. In multivariable analysis, patients with symptoms
#14 days tended to have increased rate of stroke.
Conclusions: CEA can be performed in symptomatic
patients with a 30-day stroke and death rate of 2.6%, but
there was a trend to increased rate of stroke if the opera-
tion was performed #14 days after onset of symptoms. Pa-
tients with repeated transient ischemic attacks, operated
on #2 days, had the highest risk of stroke. For this select
group of symptomatic patients, outcomes quoted based on
prospective randomized trials may not apply.
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Objectives: The objective of this study is to identify
risk factors for suboptimal medical therapy among patients
undergoing surgical bypass and percutaneous interventions
for symptomatic peripheral arterial disease (PAD).Methods: The Vascular Study Group of Greater
New York (VSGGNY) database was used to identify all
patients undergoing percutaneous therapy or surgical
bypass for PAD (2011-2013). Bivariate analyses were
performed to identify factors associated with preoperative
statin use and antiplatelet therapy. Multivariate relative
risk regression models were developed to identify pa-
tients at risk for suboptimal medical therapy.
Results: A total of 1030 patients underwent endo-
vascular therapy (n ¼ 822 [80%]) or surgical bypass
(n ¼ 208 [20%]) for symptomatic peripheral arterial dis-
ease (57.2% claudication, 15% rest pain, 27.8% tissue
loss). Preoperative statin use was observed in 59%. An-
tiplatelet therapy was observed in 79% of patients.
Bivariate analysis revealed reduced statin use among pa-
tients without other cardiovascular risk factors such as
hypertension (63% vs 39.3%; P < .0001) and coronary
artery disease (CAD) with prior cardiac revasculariza-
tion (coronary artery bypass grafting [CABG]/percuta-
neous coronary intervention [PCI]; 75.2% vs 47.4%; P
< .0001). Multivariate relative risk regression conﬁrmed
increased statin use among patients with other cardio-
vascular risk factors including hypertension (1.14
[1.02-1.27]; P ¼ .02), and CAD with prior CABG/
PCI (1.22 [1.13-1.31]; P < .0001). There was a clear
trend towards reduced statin use in patients aged >80
(0.92 [0.84-0.1.0]; P ¼ .059). By multivariate regres-
sion, antiplatelet therapy use was associated with CAD
and prior CABG/PCI (1.11 [1.04-1.17]; P ¼ .0015)
and prior peripheral revascularization (1.07 [1.01-
1.13]; P ¼ .03).
Conclusions: Patients with symptomatic PAD, but
without an antecedent cardiovascular history, are less likely
to be optimally managed with statins and antiplatelet ther-
apy preoperatively and should be actively targeted for med-
ical optimization by vascular specialists.
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